Additional studies are needed to verify the role of EGFR overexpression in artesunate resistance and to determine if EGFR inhibitors could sensitize ovarian cancer models, which would otherwise harbor innate resistance, to artesunate treatment. This evidence concerns the gene EGFR and ovarian carcinoma.